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Abstract BPP-BrachyNH2 is a proline-rich oligopeptide (PRO) firstly identified in skin secretion of the frog 
Brachycephalus ephippium, which possess in vitro inhibi- tory activity of angiotensin-I converting enzyme (ACE) and 
endothelium-dependent vasorelaxant activity. Consid- ering its potential application in the treatment of cardio- vascular 
diseases, the present work assessed the toxicological profile of the BPP-BrachyNH2. The in silico toxicity prediction was 
performed from the best model obtained through the optimization of the FASTA query peptide.   This   prediction   
study   revealed   that   BPP-BrachyNH2 induced high predicted LD50 values for both humans and rats, and then is well-
tolerated in the recom- mended range. The MTT assay was applied for the in vitro cytotoxic evaluation in murine 
macrophages. In this assay, a decrease of cell viability was not observed. The in vivo acute toxicological study was 
performed after the intraperitoneal administration of BPP-BrachyNH2 at doses of 5 and 50 mg/kg. After intraperitoneal 
administration, no death, alterations in behavioral parameters or weight gain curve was observed, as well as none in 
the serum bio- chemical parameters, and gross pathological and histopathological  analyses. .These  observations  
demon strates an acceptable safety profile for BPP-BrachyNH2, leading towards further studies focused on investigation 
of pharmacological and therapeutical applications for this peptide. 
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Introduction 
 
Proline-rich oligopeptides (PROs) represent a class of peptides firstly isolated from the Bothrops jararaca venom, which 
present proline residues at their C-terminal portions and inhibitory activity of the angiotensin-I converting enzyme 
(ACE) as well as the potentiation of bradykinin effects (Camargo et al. 2012; Morais et al. 2013). Fur- thermore, 
secretions and venoms from other animals, such as amphibians and scorpions have also been described as a potential 
source of PROs with potential applications (Conceic¸a˜o  et  al.  2007;  Verano-Braga  et  al.  2008). 
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 Fig. 1 MS spectra of BPP- 
BrachyNH2, [M?H]
? = 906.93 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2 MS/MS spectra of BPP-BrachyNH2, [M?H]
? = 906.92, acquired in an UltrafleXtreme MALDI-TOF/TOF 
 
Interestingly, the peptide BPP-BrachyNH2 (Figs. 1, 2) 
obtained from the skin secretion of the frog Brachy- 
cephalus ephippium induces endothelium-dependent 
vasorelaxant effect mediated by nitric oxide and in vitro 
inhibitory activity of ACE (Arcanjo et al. 2015). 
The application of in silico (computer-based) modeling 
in the search for lead compounds is a promising endeavor 
in drug discovery, since it often accelerates the process and 
cuts down costs (DiMasi et al. 2003). Virtual screening 
methods are useful because, in principle, they narrow down 
the  number  of  compounds  to  be  actually  tested   in 
biological assays. This is practicable when the in silico 
scoring methods are sufficiently able to discriminate 
between active and inactive ones (Kubinyi 1998; Klebe 
2006). 
Acute toxicity studies in animals are commonly applied 
in order to attend a sort of requirements related to con- 
trolled risks for human health and the environment. An 
estimated lethal dose in 50% of animals in an experiment 
(LD50) usually accomplishes the classification require- 
ments for all regulatory authorities in chemicals, pharma- 
ceuticals, consumer goods in general and pesticides. The 
  
 
 
 
 
information obtained in these studies are useful to set doses 
in repeat-dose studies, and preliminarily identify some 
possible target organ of toxicological effects, as well as to 
provide relevant information for selection of doses in Phase 
1 studies or overdose in humans (CDER 1996; OECD 
2002a). 
Considering the potential therapeutic applications of 
BPP-BrachyNH2, its toxicological profile was assessed by 
in silico, in vitro and in vivo approaches, and reported in 
this study. 
 
 
Experimental 
 
Synthesis, Purification and Characterization 
of BBP-Brachy-NH2 
 
The synthesis of the octapeptide BPP-BrachyNH2 
(WPPPKVSP) was carried out manually, with a standard 
Fmoc (N-(9-fluorenyl)methoxycarbonyl) chemistry (Fields 
and Noble 1990) starting from a Rink-amide-MBHA resin 
(0.59 mmol/g, Peptides International, Louisville, KY, 
USA). F-moc-protected amino acids (Peptides Interna- 
tional, Louisville, KY, USA) were used in four-fold molar 
excess  relative  to  the  nominal  scale   of   synthesis 
(1.2 mmol). Couplings were performed with 1,3-diiso- 
propylcarbodiimide/ethyl 2-cyano-2-(hydroxyimino) acet- 
ate (DIC/Oxyma) in N,N-dimethylformamide (DMF) for 
2–3 h. Side chain protected groups were tert-butyl for Ser, 
and Boc for Lys and Trp. Amino groups deprotections were 
conducted by  4-methylpiperidine/DMF  (1:4, v:v) for 20–
30 min. Removal of side chain protection and cleavage of 
the peptide from the resin were performed by the use of 
10.0 mL TFA:water:tioanisol:ethanodithiol:triisopropylsi- 
lane (86:5.0:5.0:2.5:1.0, v:v:v:v:v) with addition of 1 g 
phenol for 90 min at room temperature under shaking. 
After solvent evaporation under nitrogen, the peptide was 
precipitated by addition of cold diisopropyl ether, collected 
by filtration and washed four times with cold diisopropyl 
ether. Extraction was performed with 200 mL H2O:ACN 
(1:1, v:v) and crude peptide was lyophilized. Purification 
was performed using a preparative HPLC system (LaPrep 
Sigma), with LP1100 Quaternary LPG pump injection with 
fractionation valve. The elution conditions consisted of a 
linear gradient from 10 to 30% of acetonitrile in water. The 
eluent was monitored at the absorbance of 220 nm, and 
products corresponding to absorbing peaks were collected. 
Purity and molecular mass determination of the synthetic 
peptide (BPP) were performed using a MALDI-TOF/TOF 
mass  spectrometer  (UltrafleXtreme,  Bruker  Daltonics) 
water and their concentrations were determined according 
to tryptophan molar absorptivity (5550 M
-1
/cm) at 280 nm 
(Arcanjo et al. 2015). 
 
In Silico Toxicity Prediction 
 
The toxicity analysis were performed by using pkCSM (Pires 
et al. 2015a), an in silico tool web server maintained by 
VLS3D (Cambridge University). The entry was the best 
model obtained through the optimization of the FASTA 
query peptide by AMMP (Fig. 3), a full-featured molecular 
dynamics program to manipulate both small molecules and 
macromolecules including proteins, nucleic acids and other 
polymers (Pedretti et al. 2004). The structure received the 
Gasteiger charges and AMBER field force and submitted to 
minimization using a genetic algorithm, through 3000 steps. 
The conformational search was realized by using the 
Boltzmann jump method, with flexible and psi torsions, at 
300 K and RMSD equal to 60.00. The Gibbs free energy to 
the best conformer generated was calculated through Swiss- 
PDBViewer (Kaplan and Littlejohn 2001). Other physico- 
chemical properties were also calculated, such as molecular 
weights (MW), lipophilicity (logP), rotatable bonds (NRB), 
polar surface area (PSA), number of hydrogen bond accep- 
tors (HBA) and number of hydrogen bond donors (HBD). 
 
Animals 
 
Swiss and BALB/c female mice (25–30 g, 2 months) were 
used. The animals were maintained throughout the study 
period  at  12 h  light/dark   cycle   and   temperature   of 
23 ± 2  C), with free access to water and food (Purina- 
 
 
Fig. 3  Best optimized conformation of the peptide BPP-BrachyNH2 
TM 
operating  under  LIFT mode  for  MS/MS  experiments in solution. The molecular physicochemical properties are described = 906.119; LogP = -2.206; NRB = 26; 
(Figs. 1, 2). Purified peptide was obtained with 96% based 
on starting resin. Stock peptide solutions were prepared in 
as follows: MW (g/mol) 
HBA = 11; HBD = 7; PSA = 380.105; and Gibbs free 
energy = 414.412 kJ/mol 
  
 
Nestle´, Sa˜o Paulo, SP, Brazil). The experimental proce- 
dures were performed according to recommendations of 
the Organization for Economic Co-operation and Devel- 
opment (OECD), and performed with approval by the 
Ethics Committee for Animal Experimentation from the 
Federal University of Piauı´, Brazil (permission no. 
008/2012). 
 
Obtention and Cultive of Murine Peritoneal 
Macrophages 
 
Peritoneal macrophages were obtained from male BALB/c 
mice.  Three  days  after  intraperitoneal  administration  of 
1.5 mL of 3.0% thioglycollate, animals were euthanized, and 
immersed in 70% alcohol for 1 min. Then, 8 mL of sterile PSS 
was added in the peritoneal cavity, and the solution containing 
peritoneal macrophages was aspirated and transferred to a 
sterile tube, and then submitted to two centrifugations at 
1500 rpm and 4 C during 10 min, with repeated washings 
with sterile saline (0.9% NaCl). Afterwards, the supernatant 
was discarded and the cells re-suspended in 2 mL of RPMI 
1640 medium supplemented with fetal bovine serum (10% 
FBS), penicillin (10,000 IU/mL), and streptomycin (10 mg/ 
mL). The counting of viable macrophages was carried out in a 
Neubauer chamber and Blue Trypan staining, for analysis of 
cell viability (Rodrigues et al. 2015). 
 
In Vitro Cell Viability of Murine Macrophages 
by MTT Assay 
 
The evaluation of the cytotoxic activity of BPP-BrachyNH2 
in BALB/c murine macrophages was performed by MTT 
assay. Briefly, macrophages (1 9 106/well) were incubated 
in 96-well plates with 100 lL of RPMI 1640 medium 
(Sigma, St. Louis, USA) at 37 C and 5% CO2 during 4 h. 
The BPP-BrachyNH2 was incubated at different concentra- 
tions (10
-12–10-5 M) during 48 h, and 10 lL of MTT (3-
[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bro- 
mide) was added in each well from a stock solution at 5 mg/ 
mL in PBS, and was incubated during 4 h. Rightly after, the 
423), with modifications (OECD 2002b). Female Swiss mice 
were divided in three groups with three animals each, one 
control group intraperitoneally treated with saline (0.1 mL/ 
10 g body weight), and two other groups intraperitoneally 
treated with BPP-BrachyNH2 at doses of 5.0 and 50 mg/kg 
(5.5 and 55 lmol/kg), respectively. The doses were chosen 
based on previous studies with other PROs, where the highest 
active doses up to 0.75 lmol/kg (ca. 73-fold lower than the 
chosen doses) were reported (Camargo et al. 2012; Morais 
et al. 2013). After the first week of observations, the treat- 
ments were repeated on other three groups of three animals 
each according to the presence or absence of death, totaling 
six animals per treatment. 
 
Evaluation of Clinical and Behavioral Parameters 
 
After administration of BPP-BrachyNH2, the animals were 
monitored during the first 8 h in order to observe the 
occurrence of death. After 24 h, the observation time for 
each group was around 30 min to 1 h. The animals were 
weighed daily, as well as clinical and behavioral parame- 
ters were evaluated according to the Guidance Document 
on the Recognition, Assessment and Use of Clinical Signs 
from OECD (OECD 2002c). The main evaluated endpoints 
are listed in Table 1. 
 
Evaluation of Serum Biochemical Parameters 
 
After 14 days of observation, animals were anesthetized 
with sodium thiopental (45 mg/kg), and then blood sam- 
ples were collected from orbital plexus by a glass capillary 
tube and collecting tubes with coagulation activator and 
separator gel (Vacuette, Greiner Bio-One, Germany). The 
material was centrifuged at 3500 rpm during 10 min, and 
then the following biochemical parameters were evaluated: 
glucose, urea, creatinine, aspartate aminotransferase 
(AST), alanine aminotransferase (ALT), alkaline phos- 
phatase (ALP), gamma-glutamyl transferase (GGT), lactate 
dehydrogenase (LDH), total cholesterol, and triglycerides. 
The tests were performed using commercial kits following 
  
supernatant was discarded and 100 lL of DMSO was added 
to each well. The plate was stirred during 30 min in order to 
completely dissolve the formazan salt. The absorbances 
were   read   at   550 nm   (absorbance   microplate   reader 
the   manufacturer’s instructions   (LABTEST 
Labtest, Lagoa Santa, MG, Brazil). 
 
Evaluation of Body and Relative Organ Weights 
Pleno; 
TM 
ELx800 , BioTek Instruments, USA). The results were 
expressed as CC50 (mean cytotoxic concentration for 50% of 
the cells) with the confidence intervals calculated by non- 
linear regression (Rodrigues et al. 2013, 2015). 
 
In Vivo Assessment of Acute Toxicity in Mice 
 
The toxicological evaluation of BPP-BrachyNH2 was per- 
formed based on the Acute Toxic Class Method (OECD no. 
The animals were daily weighed in order to obtain the 
dose–effect curve. After 14 days, the animals were anes- 
thetized and then euthanized with a lethal dose of sodium 
thiopental (100 mg/kg, i.p.). Right after, the organs (heart, 
lung, stomach, spleen, liver and kidneys) were removed for 
gross pathology analysis (texture, consistency and color). 
Then, the organs were weighed in order to calculate the 
relative weight, as follows: 
  
 
 
Table 1  Computer-aided toxicity parameters and recommended ranges to oral active compounds 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2  Clinical and behavioral signs assessed after acute adminis- 
tration of BPP-BrachyNH2 at doses of 5.0 and 50 mg/kg i.p. 
 
 
Evaluated signs Time (min) 
 
 
30 60 120 180 240 
 
 
Stimulant 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Deaths 0 0 0 0 0 
 
 
(0) Without effect 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Histopathological analyzes were performed by a single 
observer and the photographic record made in digital camera 
coupled to an optical microscope. 
Model name Unit Preferred Predicted value 
Hepatotoxicity Categorical No Yes 
Skin sensitisation Categorical No No 
AMES toxicity Categorical No No 
Max. tolerated dose (human) log mg/kg day Up to 0.477 0.255 
hERG I inhibitor Categorical To be interpreted relative to the bioactive concentration No 
hERG II inhibitor Categorical To be interpreted relative to the bioactive concentration Yes 
Oral rat acute toxicity (LD50) mol/kg To be interpreted relative to the bioactive concentration 2.694 
Oral rat chronic toxicity (LOAEL) log mg/kg day To be interpreted relative to the bioactive concentration 3.547 
 
Hyperactivity 0 0 0 0 0 
Aggressiveness 0 0 0 0 0 
Tremors 0 0 0 0 0 
Convulsion 0 0 0 0 0 
Piloerection 0 0 0 0 0 
Depressive      
Ptosis 0 0 0 0 0 
Sedation 0 0 0 0 0 Fig. 4  Evolution of the weight gain of the animals from control 
Anesthesia 0 0 0 0 0 group   (filled   square)   or   intraperitoneally   treated   with   BPP- 
Ataxia 0 0 0 0 0 BrachyNH2 at doses of 5.0 (triangle) and 50 (filled inverted triangle) 
Righting reflex 0 0 0 0 
0 
mg/kg. Data represented as mean ± SEM, n = 6 animals per group 
Catatonia 0 0 0 0 0 
Analgesia 0 0 0 0 0 ½body weight ðgÞ=animal weight on the day of necropsy ðgÞ  
Loss of corneal reflex 0 0 0 0 0 100: 
Loss of auricular reflex 0 0 0 0 0 
Autonomic nervous system-related 
Diarrhea 0 0 0 0 0 Histopathological Analyses 
Constipation 0 0 0 0 0  
Lacrimation 0 0 0 0 0 After euthanasia, the organs (liver, spleen, kidney and lung) 
Salivation 0 0 0 0 0 were carefully removed and fixed in 10% formaldehyde 
Cyanosis 0 0 0 0 0 solution during 72 h. For the histopathological analysis, the 
Others      fixed organs were dehydrated in solutions with increasing 
Ambulation 0 0 0 0 0 concentrations of ethanol (70, 80, 90 or 99.9%), diaphanized 
Self-cleaning 0 0 0 0 0 in xylene (39), impregnated and embedded in warm paraffin 
Climb 0 0 0 0 0 at 60  C. Then, the histological sections were obtained by a 
Vocalization 0 0 0 0 0 microtome (5 lm thick). Then, histological sections were 
Abdominal writhes 0 0 0 0 0 submitted to the hematoxylin and eosin staining method. 
 
  
 
Table 3  Serum biochemical 
parameters of female Swiss 
mice 14 days after the treatment 
with single intraperitoneal dose 
of BPP-BrachyNH2 (5 and 
50 mg/kg, i.p.) 
 
 
 
 
 
 
 
 
 
The values are expressed as mean ± SEM (n = 6/group) 
* p \ 0.05 when compared with control; Student t test for non-paired samples 
AST aspartate aminotransferase, ALT alanine aminotransferase, ALP alkaline phosphatase, GGT gamma- 
glutamyl transferase, LDH lactate dehydrogenase 
 
 
Table 4 Relative organ weights of female Swiss mice 14 days after 
the treatment with single intraperitoneal dose of BPP-BrachyNH2  (5 
and 50 mg/kg, i.p.) 
 
dose, oral rat acute toxicity (LD50), oral rat chronic toxi- 
city, human ether-a`-go-go related gene (hERG) inhibitors, 
   hepatotoxicity, skin sensitization and mutagenicity were 
Organs (g)       Control BPP-BrachyNH2 (i.p.) 
 
 5 mg/kg 50 mg/kg 
Lungs 0.656 ± 0.042 0.674 ± 0.042 0.610 ± 0.037 
Heart 0.478 ± 0.026 0.555 ± 0.030 0.463 ± 0.020 
Liver 4.909 ± 0.084 5.036 ± 0.429 4.824 ± 0.293 
Spleen 0.395 ± 0.037 0.362 ± 0.034 0.348 ± 0.048 
 Kidneys 1.227 ± 0.052     1.282 ± 0.075     1.185 ± 0.049  
The values are expressed as mean ± SEM (n = 6/group) 
 
Statistical Analyses 
 
Values are expressed as mean ± standard error of the 
mean (SEM). Differences between groups were determined 
by Student’s t test analysis for unpaired samples. The 
results   were   considered   statistically   significant   when 
p \ 0.05. 
 
 
Results and Discussion 
 
The distributions of the peptide MW, logP, number of HBA 
and number of HBD were evaluated for the peptide and 
represented in Fig. 3. In addition, the data of NRB and PSA, 
which have been used as an additional criterion to test for 
favorable metabolism and pharmacokinetics outcomes, were 
determined (Ntie-Kang 2013). The Gibbs free energy cal- 
culated for BBP-BrachyNH2 was 414.412 kJ/mol. 
In the study of the prediction of peptide toxicity profile, 
several  predictors  including  human  maximum  tolerated 
used. These parameters and descriptors are presented in 
Table 1. Together, the toxicity profile of the peptide 
revealed that BPP-BrachyNH2 is well-tolerated by humans 
and rats, with the values in the recommended range. 
Likewise, the AMES mutagenicity prediction revealed 
negative for the peptide, indicating absence of BPP- 
BrachyNH2-induced mutagenic activity, as well as absence 
of skin sensitization. 
The pkCSM hepatotoxicity prediction is based on the 
human liver-related side effects of 531 different com- 
pounds. If the compound is related with at least one liver 
pathological or physiological event, the prediction returns 
positive result (Fourches et al. 2010; Pires et al. 2015b). 
Although the in silico study predicted hepatotoxicity for 
the BPP-BrachyNH2,  no  alteration was  observed  in the 
in vivo serum biochemical parameters, such as AST, ALT, 
ALP, and GGT, as well as in the liver histopathological 
analysis (described below). 
The blockage of the voltage-dependent ion channel 
encoded by hERG may affect the cardiac repolarization, 
leading to drug-induced QT interval prolongation, which is a 
critical side-effect of non-cardiovascular therapeutic agents 
(Vandenberg et al. 2012; Wang et al. 2013). The pkCSM 
prediction of hERG inhibition is based on two models. The 
hERG I model is based on the IC50 values of 368 compounds, 
and classify the compounds as strong inhibitors (IC50 \ 1 -  
lM), and non-blockers exhibiting moderate (1–10 lM) or 
weak (IC50 C 10 lM) inhibition (Marchese Robinson et al. 
2011). The hERG II model is based on the preliminary data of 
806 compounds, also considering molecular parameters, 
Parameters Control BPP-BrachyNH2 (i.p.)  
  5 mg/kg 50 mg/kg 
Glucose (mg/dL) 186.0 ± 18.7 132.8 ± 9.0* 136.5 ± 6.9* 
Urea (mg/dL) 63.5 ± 8.5 64.6 ± 3.4 50.7 ± 3.1 
Creatinine (mg/dL) 0.2 ± 0.0 0.2 ± 0.0 0.2 ± 0.0 
AST (U/mL) 96.2 ± 11.0 120.0 ± 26.0 85.5 ± 16.6 
ALT (U/mL) 58.0 ± 8.2 76.6 ± 6.3 48.7 ± 6.0 
ALP (U/mL) 88.0 ± 13.6 87.4 ± 4.4 114.8 ± 9.5 
GGT (U/mL) 2.3 ± 1.4 1.1 ± 0.5 1.6 ± 0.7 
LDH (U/mL) 648.7 ± 70.9 899.2 ± 130.3 599.0 ± 40.1 
Total cholesterol (mg/dL) 82.3 ± 6.4 78.8 ± 6.5 77.3 ± 3.0 
Triglycerides (mg/dL) 83.3 ± 9.7 77.4 ± 11.3 72.7 ± 1.3 
 
  
 
 
 
 
Fig. 5 Photomicrographies of histological sections obtained from the 
liver (a1, b1, c1), spleen (a2, b2, c2), kidney (a3, b3, c3) and lung (a4, 
b4, c4) of animals (n = 3) intraperitoneally treated with vehicle (a) or 
BPP-BrachyNH2 at doses of 5.0 (b) and 50 (c) mg/kg. After 14 days, 
the animals were euthanized, and the organs were removed and 
processed to histopathological analysis. The results showed that the 
treatment with BPP-BrachyNH2 did not show any changes compared 
with vehicle. Hematoxylin and eosin staining 
 
such as solubility and MW (Wang et al. 2012). Our in silico 
results revealed a positive result for hERG II but not for the 
hERG I. Although these results suggest a possible BPP- 
BrachyNH2-induced cardiotoxic effect, the differences 
between the applied models should be considered, as well as 
the different applied datasets in the same model could show 
  
 
variability in the final results (Marchese Robinson et al. 
2011). 
In vitro cytotoxicity assays are essential in the early 
stages of the development of new drugs, because they are 
able to estimate the starting dose and the range of con- 
centrations to be used in the in vivo non-clinical stages 
(OECD 2010). In this study, a decrease of cell viability 
induced by BPP-BrachyNH2 in murine macrophages was 
not observed in MTT assay, suggesting  the absence of 
cytotoxicity for this peptide. 
Regarding the in vivo toxicological study, the BPP- 
BrachyNH2 (5 and 50 mg/kg) did not cause any death after 
intraperitoneal administration in Swiss female mice, indi- 
cating absence of toxicity. Interestingly, in a previous 
study, captopril was not able to induce death up to the 
concentration of 2000 mg/kg, with LD50 of 3255 mg/kg in 
female Swiss mice (Imai et al. 1981). Therefore, captopril 
is also considered as a safe drug. Besides, during the first 
24 h after treatment and throughout 14 days, no clinical or 
behavioral sign of toxicity was observed (Table 2). The 
general activity of mice was not altered during the period 
of study, demonstrating a good health condition. 
The evaluation of the body weight curve of the ani- 
mals is an important indicator for the toxicological 
assessment of a substance, generally related to alterations 
in the consumption of water and  food  (OECD  2002c). 
The acute administration of BPP-BrachyNH2 did not 
promote alterations in the body weight curve of mice 
throughout the treatment period (Fig. 4). Besides, a pre- 
vious study report that captopril up to 4000 mg/kg is not 
able to alters the body weight of female Swiss  mice 
(Imai et al. 1981). 
Furthermore, no marked alterations were observed in the 
serum biochemical parameters when compared with the 
reference ranges observed for animals from different 
standardized animal houses (Santos et al. 2010). However, 
a mild alteration of blood glucose levels was observed 
when compared with vehicle (Table 3), suggesting further 
studies for a possible BPP-BrachyNH2-induced hypo- 
glycemic effect in experimental  models of diabetes, 
thereby enhancing the potential application of this peptide 
in the treatment of cardiovascular diseases (Arcanjo et al. 
2015). 
The evaluation of the organ weight is a useful screening 
tool in the characterization of effects related to general 
toxicity studies (Michael et al. 2007). After treatment with 
BPP-BrachyNH2, no changes were  also found in organ 
weights (Table 4). Besides, no significant change was 
observed in the gross pathological examination of the 
organs (lungs, heart, liver, spleen and kidneys), as well as 
morphological changes were not observed in the histolog- 
ical sections (Fig. 5). 
Conclusions 
 
The in silico toxicity prediction indicated a well-tolerated 
toxicological profile for the BPP-BrachyNH2. Besides, this 
peptide did not presented any signal of in vivo acute toxicity 
after single dose intraperitoneal administration. This study 
indicates an acceptable safety profile for studies in animal 
experimental models focused on the investigation of the 
potential pharmacological, biotechnological and therapeutic 
applications of this peptide. In this sense, these findings 
reinforce further studies regarding the toxicological effects 
of in vivo chronical exposure to BPP-BrachyNH2. 
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